News releases - Merck.com
Oct 28, 2024 · Merck Announces Third-Quarter 2024 Financial Results. October 28, 2024. Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) October 24, 2024.
Merck KGaA Beats Estimates on Boost From Life Science Unit
3 hours ago · Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic slump alongside positive growth trends in its other two businesses.
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in …
Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. WINREVAIR logo (Graphic: Merck & Co., Inc.)
Merck Announces Second-Quarter 2024 Financial Results
Jul 30, 2024 · Full-Year 2024 Financial Outlook. Raises and Narrows Expected Worldwide Sales Range To Be Between $63.4 Billion and $64.4 Billion. Now Expects Non-GAAP EPS To Be Between $7.94 and $8.04; Outlook Reflects Negative Impact From One-Time Charge of Approximately $1.3 Billion, or $0.51 per Share, for the Acquisition of EyeBio.
Merck to Present New Data From GARDASIL - Business Wire
2 days ago · RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company’s 9-valent Human ...
News & Stories - Merck
Oct 9, 2024 · Check out the latest Merck news and stories! Learn more about the leading science and technology company here.
Merck Enters Two Strategic Collaborations to Strengthen AI …
Sep 20, 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.
FDA approves Merck's drug for rare, deadly lung condition
Mar 26, 2024 · The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients...
Merck KGaA Q3 earnings rise faster than expected on lower costs
3 hours ago · Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug development and a rebound in demand for its specialty materials.
Merck’s Covid Pill Is Authorized for High-Risk Adults - The New …
Dec 23, 2021 · Merck is expected to fulfill the federal government’s full order of enough pills for 3.1 million people, at a cost of about $700 a person, by the end of January. Pfizer is expected to provide...